3653 results for «445»
3653 results
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
Beyond the diagnosis: a qualitative exploration of women’s experiences with cardiovascular disease
21 May 2026 – From EuroPCR 2026
This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.
SCAD, PCI specific strategies
21 May 2026 – From EuroPCR 2026
This session focuses on specific percutaneous coronary intervention strategies for spontaneous coronary artery dissection (SCAD) and related coronary anomalies. It covers clinical and therapeutic aspects of adult coronary aneurysms, woven coronary anomalies, innovative stent optimization techniques, microvascular dysfunction in takotsubo syndrome, and real-world management of SCAD...
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
09 May 2023
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
EuroPCR 2026: Elixir Medical's DynamX® bioadaptor demonstrates significantly lower event rates than drug-eluting stent in long-term follow-up, including reduction in cardiovascular death
19 May 2026
Promising Safety and Efficacy Results for Supraflex Cruz in HBR Subset Analysis from FIRE Trial, with 1-Month DAPT
03 Nov 2023
Positive 3-year results from FIRE Trial demonstrate Supraflex Cruz’s safety and efficacy in elderly heart attack patients
26 Sep 2025
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
EuroPCR 2024: Late-breaking data demonstrate significant clinical advantage of Elixir Medical’s DynamX bioadaptor over standard-of-care drug-eluting stent at two years
14 May 2024
Elixir Medical’s DynamX Bioadaptor demonstrates significant improvement over contemporary drug-eluting stent in patients with acute coronary syndrome and complex lesion subsets after six months
28 Oct 2024
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
17 May 2023